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Abstract: Pathophysiologic conditions of neurodegenerative diseases are unquestionably related to
protein misfolding. The accumulation of misfolded proteins into relatively ordered structures such
as fibrillar intracellular and extracellular amyloids results in tissue lesions that lead to neuronal loss
and brain damage. In these pathologies, the occurrence of protein aggregates suggests certain ineffi-
cient or insufficient cellular responses of those molecular chaperones that should properly assist
the folding of the client proteins. In this regard, most experimental models for neurodegenerative
diseases have demonstrated that the overexpression of molecular chaperones provides effective neu-
roprotection. A subset of these molecular chaperones corresponds to a group of proteins that exhib-
it peptidylprolyl isomerase enzymatic activity, the immunophilins. Most of the family members of
the latter group were first described as being responsible for the immunosuppressive response or
they were reported as members of the chaperone complex associated with HSP90 in steroid recep-
tor oligomers. In this article, we review some aspects of the liaison between molecular chaperones
and neurodegenerative diseases, in particular heat-shock proteins and immunophilins with demons-
trated influence on the proper function of mitochondria. This article is intended to address a field
that represents a yet critical unmet clinical need for the development of neuroprotective molecules
focused on potentially novel molecular targets.
Keywords: Immunophilins, Neurodegeneration, HSP90, FKBP51, FKBP52, Cyclophilin A.
1. INTRODUCTION
One of the most crucial properties achieved for the liv-
ing matter is the compartmentalization of the cell work in or-
ganelles.  The  generation  of  energy  from  the  cellular
metabolism is one of the most relevant duties reserved to a
major  ancient  endomembrane  factory,  the  mitochondria.
This  type of  organelle  arose almost  two billion years  ago,
most  likely  from  the  engulfment  of  an  α-proteobacterium
within the body of an ancestor of the modern eukaryotic cell
[1, 2]. In addition to being the powerhouse of the cell, mito-
chondria also perform other essential activities that are close-
ly  related  to  the  cellular  metabolism,  such  as  synthesis  of
steroid hormones, the synthesis of heme, calcium storing for
its later release, i.e. acting as a cytosolic buffer for Ca2+-de-
pendent signaling, and is also responsible for specific path-
ways leading to cell death decisions [3]. Also, mitochondria
are the primary source of endogenous reactive oxygen spe-
cies, which are regarded to be mainly responsible for the un-
avoidable process of cell aging [4].
Failures in the mitochondrial function generate diseases.
This is particularly notable for the case of neurodegenerative
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diseases, notwithstanding the normal aging processes them-
selves [5]. Most of these pathologies associate with protein
instability and the formation of protein aggregates. As a re-
sult, neuronal malfunction is produced due to the devastat-
ing effects related to cell death and miscommunications be-
tween brain cells. Therefore, the affected individual shows
severe problems to control physical movements as well as
other deficiencies related to learning ability, memory capaci-
ty, speech skills, etc. It is noteworthy that the specific causes
are so complex that they are mostly unknown or poorly un-
derstood [6], and most therapies are applied to alleviate or re-
tard the symptoms. Table 1 summarizes the most important
neurodegenerative diseases and the proteins involved in the
pathology.
Table 1. Most frequent neurodegenerative diseases due to pro-
tein misfolding and aggregation.
Disease Proteins Involved References
Alzheimer’s Disease (AD) β-Amyloid and Tau 135, 171
Parkinson’s Disease (PD) α-Synuclein and Tau 26, 62
Huntington’s Disease (HD) Huntingtin 218, 222
Prion PrP 128, 202
Tauopathies Tau 44, 127
Lewy’s Bodies Dementia (LBD) α-Synuclein and ubiquitin 200, 201
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Molecular chaperones are a family of proteins that play a
critical role in both the regulation of mitochondrial functions
and neurodegenerative diseases. The term ‘chaperone’ refers
to proteins that assist others in their proper folding and bio-
logical functions. Classically, chaperones protect client-pro-
teins  from  misfolding,  aggregation  and  denaturation,  thus
preserving the protein homeostasis of the cell (or proteosta-
sis) [7]. The expression level of the subfamily of the chaper-
one  family  is  highly  induced  by  temperature  changes,  in
which  case  they  are  named  ‘heat-shock  proteins’  (HSPs).
This implies that even though all HSPs are members of the
chaperone family, not all chaperones are necessarily HSPs.
Nonetheless, all of them share the same functional charac-
teristics.  These  proteins  play  a  critical  role  in  preserving
and/or reverting the protein misfolding and aggregation that
results from mitochondrial dysfunction or cell exposure to
harmful stimuli (Fig. 1). This imbalance of protein stability
usually leads HSPs to join the damaged protein to block or
hinder  the  aggregation  process  of  misfolding.  Also,  they
may have a role in promoting bonding to ubiquitin and pro-
teasomal degradation.
Fig. (1). The schematic interplay between mitochondrial dysfunc-
tion and chaperone function. High levels of reactive oxygen spe-
cies (ROS) lead to modifications of native proteins A and B, which
become misfolded (A’ and B’). This may occur because of failures
in the protein folding machinery as a consequence of harmful stim-
uli or due to genetic reasons. Molecular chaperones (shown in red)
may  stabilize  the  damaged  protein  (cases  A  and  B),  preventing
and/or  reverting  protein  aggregation.  In  some  cases,  the  proper
chaperone is damaged (case A’) and cannot play its role, such that
the  misfolded protein  A’  is  targeted to  proteasomal  degradation,
which happens in the best case. If this would not occur, the misfold-
ed proteins can precipitate or form aggregates and fibril structures
that  cannot  be  efficiently  reversed  by  molecular  chaperones.
Nonetheless, chaperones can also facilitate proteasomal degrada-
tion of misfolded proteins. (A higher resolution / colour version of
this figure is available in the electronic copy of the article).
2. MITOCHONDRIAL HEAT-SHOCK PROTEINS
Even  though  a  few numbers  of  mitochondrial  proteins
are encoded on the mitochondrial genome, most of the pro-
teins belonging to this organelle are encoded by genes that
reside in the nuclear genome of the cell. Therefore, there ex-
ists  a  complex  biogenesis  pathway  for  mitochondrial  pro-
teins that must be synthesized in the cytosol and is required
to be imported into the organelle. There is an extra complica-
tion related to the limited dimensions of the mitochondrial
translocation channels,  such that  the protein must  traverse
the  double  system of  membranes  in  an  unfolded state  [8].
The  proper  recognition  of  mitochondrial  preproteins  re-
quires the accessibility of diverse N-terminal sequences or
internal translocation signal sequences by mitochondrial sur-
face receptors. In most cases, this fact precludes the acquisi-
tion of the final active conformation of the protein, a pheno-
menon that requires the assistance of chaperones. There are
four important groups of HSPs implicated in mitochondrial
protein homeostasis that are involved in protein transloca-
tion of the client-factor HSP90, HSP70, HSP60, and HSP27.
Except for the small HSP, the other chaperones possess in-
trinsic ATPase activity,  and both HSP70 and HSP90 have
specific mitochondrial homologs named respectively Mor-
talin (mtHSP70) [9] and tumor necrosis factor receptor-asso-
ciated protein-1 (TRAP1) [10].
2.1. HSP60
HSP60 proteins form a subfamily of chaperones whose
genes encode for heat-inducible 60-kDa proteins. Actually,
they  are  classified  as  chaperonins,  i.e.  oligomeric  high-
molecular  weight  chaperones  capable  of  folding  proteins
that cannot be folded by simpler chaperone systems [11]. It
is  regarded that  approximately 80% of HSP60 is scattered
throughout the mitochondria, where it catalyses the proper
folding of mitochondrial matrix proteins [12]. The remain-
ing pool of HSP60 resides in the endoplasmic reticulum, the
cell surface, peroxisomes and/or cytosol. The non-mitochon-
drial  HSP60  retains  the  mitochondrial  localization  signal
and is also called naïve HSP60 [13]. The targeting sequence
is  cleaved  by  proteases  when HSP60 is  imported  to  mito-
chondria yielding the so-called ‘mature’ HSP60 protein.
HSP60 shows a barrel-shaped structure of two stacked
rings of 7 subunits,  each limiting a cavity with a lining of
largely hydrophobic amino acid residues. This cavity is capa-
ble of accommodating unfolded peptides up to a size of ~50-
kDa. Other small chaperonin termed HSP10 covers the open-
ing of the 7-subunits ring by binding to the apical areas of
them. The inner lining of the cavity undergoes an ATP-de-
pendent conformational change becoming more hydrophilic
and generating a space where the ‘analysed’ foreign polypep-
tide folds without the interference of external protein con-
tacts. Then, HSP10 opens and the substrate is released for
processing and assembly events that ultimately lead to the fi-
nal active folded protein. Functionally impaired or damaged
HSP60/HSP10 complexes lead to mitochondrial dysfunction
and deficient physiologic functions that are deemed to be re-
lated to the onset of several diseases such as diabetes, Hashi-
moto's thyroiditis, juvenile rheumatoid arthritis, myasthenia
gravis, and chronic obstructive pulmonary diseases [14]. Im-
portantly,  it  is  also  related  to  neurodegenerative  diseases
such  as  SPG13  (Hereditary  Spastic  Paraplegia)  [15]  and
BHLD (Brain Hypomyelination Leukodystrophy) [16].
Interestingly, it has been proposed that the depletion of
soluble HSP60 is a major fact in the neuronal degeneration
associated with amyotrophic lateral sclerosis [17]. In turn,
Role of Mitochondrial Heat-shock Proteins and Immunophilins Current Drug Targets, 2021, Vol. 22, No. 00   3
the  accumulation  of  intracellular  β-amyloid  in  Alzheimer
Disease  models  was  not  significantly  affected  due  to  the
high expression levels of HSP60, but a dramatic reduction
of  its  aggregates  was  observed  by  the  combined  action  of
high  expression  level  of  HSP60  along  with  HSP70  and
HSP90 [18]. Accordingly, β-amyloid aggregation could be
inhibited in vitro by the addition of HSP60. An encouraging
observation was the good induction of specific anti-β-amy-
loid antibodies after the injection of a β-amyloid-HSP60 pep-
tide-conjugate vaccine, a response that was associated with a
significant  reduction  of  cerebral  amyloid  accumulation  in
mouse models of Alzheimer’s disease [19]. Proteomic analy-
sis of hippocampi of amyloid precursor protein (APP)-trans-
genic mice showed high levels of β-amyloid oligomers dur-
ing the early age of the animal, but no plaques were detected
in old animals, which showed altered levels of HSPs, in par-
ticular  decreased  HSP60.  Moreover,  it  was  reported  that
HSP60 favours  the  translocation  of  APP to  the  mitochon-
dria,  which  leads  to  organelle  dysfunction.  Consequently,
the precise role of HSP60 in Alzheimer’s disease is still con-
troversial  and  further  investigations  are  required  to  deter-
mine if the chaperone is either a ‘friend’ or a ‘foe’ for this
disease.
2.2. HSP70
HSP70  proteins  comprise  another  large  subfamily  of
chaperones with ATPase activity that are characterized by
its ubiquity, structural conservation and pleiotropic biologi-
cal involvement. Eukaryotes express more than a dozen of
different isotypes of HSP70s that are localized in all major
compartments of the cell [20]. Mitochondrial HSP70 is an es-
sential chaperone that is absolutely required for cellular sur-
vival  and  the  vectorial  transport  of  mitochondrial  prepro-
teins  from  the  cytosol  into  the  matrix  of  the  organelle
through the translocase complexes located in the mitochon-
drial membranes [21]. HSP70 functions are normally associ-
ated with HSP40, a co-chaperone belonging to the J- domain
proteins  or  DNA-J  like  proteins,  which  assists  HSP70  in
binding the substrate protein and stimulating ATPase activi-
ty.  The  mitochondrial  isoform  of  HSP40  is  MDJ1.  This
HSP70•MDJ1 complex encounters the completely unfolded
preprotein when it is crossing the membrane [22], a property
that mimics the function of the cytosolic isoforms of HSP70
when  they  assist  the  proper  folding  of  a  nascent  peptide
emerging  from  the  ribosome  tunnel  [23].  Even  though
HSP70•MDJ1 plays a cardinal role in the mitochondrial ma-
trix  compartment  during  the  folding  of  imported  proteins,
both  HSP60 and  HSP90 also  cooperate  actively  and  are  a
key requirement for this process.
It  is  regarded  that  high  levels  of  expression  of  HSP70
are a desirable condition to protect neuronal cells against pro-
teolytic and mitochondrial stress in both normal conditions
and neurodegenerative diseases such as Alzheimer’s, where
the conjunct overexpression of the chaperone and the E3-li-
gase Parkin enhances the protection of cells in cases of β-
amyloid-induced mitochondrial dysfunctions [24]. In Parkin-
son's  disease,  the  overexpression  of  HSP70  protects  cells
against proteolytic and mitochondrial stress in a similar man-
ner to that brought about by Parkin overexpression [25]. In-
terestingly, rising the cytoplasmic expression of α-synuclein
at the nM range induces the expression of HSP70, which in
turn restricts the accumulation of α-synuclein and its cytotox-
ic  effects  [26].  HSP70 also reduces  poly(Q)-mediated cell
death by protecting against ROS harmful effects and by in-
hibiting the activity of cytochrome-c and, therefore, apopto-
sis [27]. Accordingly, the overexpression of HSP70 in Hunt-
ington disease mice models also inhibits polyQ accumula-
tion [28]. On the other hand, reduced HSP70 expression has
been found in the spinal cord tissues of patients with amy-
otrophic lateral sclerosis (ALS) [29]. Also, the knock-down
of HSP70 in neuroblastoma cells favours the cytoplasmic ac-
cumulation of TDP-43 [30], the major pathological marker
of ALS, suggesting a role of HSP70 in suppressing the gener-
ation of toxic forms of this primarily nuclear protein belong-
ing to the hnRNP family.
2.3. TRAP1
Mitochondrial HSP90 is known as TRAP1 and HSP75.
It  is  localized  in  the  mitochondrial  matrix  [31],  although
some degree of extra-mitochondrial  localization cannot be
ruled out. TRAP1 exerts protective effects on mitochondria
preventing oxidative stress-induced cell death thanks to the
inhibition of the permeability transition pore opening [32],
an effect that occurs by inhibition of CyPD (cyclophilin D)
and  indirectly  due  to  the  modulation  of  the  ROS  levels.
Even though the homology of TRAP1 with cytosolic HSP90
is significant, both chaperones seem to differ in their functio-
nal properties and TRAP1 was incapable to functionally re-
place  HSP90  when  it  was  expressed  in  the  cytosol  [31].
However, TRAP1 mitigates the proapoptotic toxicity of α-
synuclein and prevents the formation of fibrils, and both pro-
teins colocalize in mitochondria [33]. In Parkinson's disease
models,  it  was  reported  [34]  that  the  overexpression  of
TRAP1 fully rescues mitochondrial impairments associated
with PINK1 (phosphatase and tensin homolog (PTEN)-in-
duced kinase-1) loss of function and also mechanisms relat-
ed  to  Parkin.  Interestingly,  TRAP1 is  released  from mito-
chondria into the cytosol of dopaminergic neurons following
a 6-hydroxy-dopamine stimulation, a translocation that can-
not be emulated by apoptotic inducers such as etoposide or
staurosporine [35].
More recently, it was proposed that S-nitrosylation of the
Cys501 residue of TRAP1 favors its loss of activity and the
chaperone degradation [36]. Also, this fact may have rele-
vance in aging and age-related diseases such as neurodegen-
eration [37], processes that are closely related to pathologi-
cal states due to mitochondrial dysfunctions. Whether or not
β−amyloid is imported into mitochondria remains uncertain.
Thus, it was reported that the Tom complex can transport β-
amyloid  into  the  mitochondrial  matrix  [38],  but  another
study showed that  the  β-amyloid  interferes  with  the  mito-
chondrial import of nuclear-encoded mitochondrial proteins
[39]. One possible explanation for this controversy would be
the possible mitochondrial import of the β-amyloid before it
forms aggregates.
4   Current Drug Targets, 2021, Vol. 22, No. 00 Daneri-Becerra et al.
Fig. (2). Structural domains of the most abundant immunophilins expressed in the nervous system. The signature domain of the family is the
PPIase domain (orange box). HSP90-binding members show TPR domains (green box), a property that is not shared by the two smallest
members of the family, FKBP12 and CyPA/CyP17, which are responsible for immunosuppressive action when they are bound to the proper
ligand. FKBP38 is a constitutive mitochondrial immunophilin, thanks to the MT targeting sequence shown at the N-terminal end (blue box).
It has a poorly characterized calmodulin-binding domain (CBD, purple box), which is also present at the C-terminal end of FKBP52. (A high-
er resolution / colour version of this figure is available in the electronic copy of the article).
2.4. HSP27
The so-called small HSPs have a molecular weight rang-
ing from 12-kDa to 43-kDa for their monomeric forms, and
are  structurally  characterized  by  the  presence  of  the  so-
called α-crystallin domain, a conserved sequence of the ho-
monymous  chaperone  protein  expressed  in  the  intact  lens
preventing aggregation of other proteins. Among the mem-
bers  of  this  subfamily,  HSP27  is  one  of  the  most  iconic
small HSP and is responsible for increasing cell viability, an-
ti-apoptotic actions, antioxidant effects, and microfilament
remodeling  [40].  Upon  phosphorylation,  HSP27  promotes
actin polymerization contributing to microfilament network
maintenance by preventing filament degeneration, which in
turn provides cell stability to proapoptotic stimuli [41]. On
the  other  hand,  in  its  unphosphorylated  form,  HSP27 pre-
vents actin assembly of wild-type proteins by actin capping
[42]. Its overexpression protects cells from oxidative stress
since HSP27 hampers the upstream production of ROS [43].
There are some studies limited to the therapeutic capabilities
of HSP27 on Alzheimer’s disease showing restoration in the
amyloid  plaque  and  tangle  formation,  HSP27-dependent
degradation of hyperphosphorylated Tau and prevention of
fibril  formation [44-46] It  has also been postulated that  in
cases of Parkinson’s disease, the kinetics of α-synuclein ag-
gregation is prevented by HSP27, the chaperone being less
effective at a faster rate of aggregation [47].
3. IMMUNOPHILINS
Immunophilins  are  a  group  of  molecular  chaperones
characterized by the presence of a PPIase domain (Fig. 2),
i.e. a relatively conserved sequence of amino acids that usu-
ally shows the enzymatic activity of PPIase (peptidylprolyl-
cis/trans-isomerase) and also binds immunosuppressive li-
gands, which in turn inhibit the enzymatic activity [48]. Ac-
cording to the type of ligand they recognize, immunophilins
are  classified  into  two  subfamilies,  CyPs  (cyclophilins)
when  they  bind  the  cyclic  undecapeptide  cyclosporine  A,
and  FKBPs  (FK506-binding  proteins)  when  they  bind  the
macrolide FK506.
The so called high molecular weight immunophilins are
characterized by the additional presence of TPR domains (te-
tratricopeptide-repeats),  α-helix  pair  repeats  that  usually
fold together  to produce a linear  solenoid domain through
which they usually bind to HSP90. Via this chaperone, the
TPR-domain immunophilins contribute to the regulation of
the biological functions of several client-proteins [49, 50].
In contrast to low molecular weight immunophilins, which
are incapable to interact with HSP90, these larger TPR-do-
main proteins are not related to immunosuppression. Actual-
ly,  only  the  smallest  members  of  each  subfamily  of  im-
munophilins, CyPA and FKBP12, are responsible for the im-
mune-suppressive effect when they are respectively activat-
ed by cyclosporine A or FK506. Thus, the immunophilin•-
drug complex inhibits calcineurin activity [51].
3.1. CyPD
The  oldest  known  mitochondrial  immunophilin  de-
scribed in the literature was CyPD [52]. It must not be con-
fused with the TPR-domain immunophilin CyP40 (40-kDa),
since at times, both proteins are named indistinctly. Human
CypD is a cytoplasm-translated globular protein of 206 resi-
dues and ~22 -kDa. Upon its transport to the mitochondria,
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its mitochondrial targeting sequence is cleaved, thus result-
ing in a mature protein with a theoretical MW of 18.9-kDa
[53].
CyPD is a protein related to the regulation of the mito-
chondrial permeability transition pore, whose opening nor-
mally leads to cell death by apoptotic mechanisms and has
also  been  implicated  in  the  ischemia-reperfusion  pheno-
menon that provokes severe injuries in multiple organs, mus-
cular  dystrophies  and  neurodegenerative  disorders  [54].
CypD is highly expressed in several nervous cell types such
as astrocytes, microglia, and neurons [55], where it plays a
significant role in excitotoxicity and cell death, especially in
cases of multiple sclerosis [56].
The mitochondrial permeability transition leads to mito-
chondrial swelling, outer membrane rupture and the release
of apoptotic mediators. Mice lacking CyPD expression are
protected from ischaemia/reperfusion-induced cell death in
vivo,  whereas CyPD-overexpressing mice show mitochon-
drial swelling and spontaneous cell death. Mitochondria iso-
lated from brains of transition pore null mice are resistant to
mitochondrial swelling and permeability transition in vitro
[57]. On the other hand, CyPD knock-out mice show a less
serious phenotype in models of autoimmune encephalomyeli-
tis  when  they  are  compared  with  wild  type  animals  [58].
Similar benefits have also been observed in CypD knock-out
mouse models of Alzheimer’s disease [59], amyloid lateral
sclerosis [60], traumatic brain injury [61], Parkinson’s dis-
ease [62], and Huntington’s disease [63]. CyPD also regu-
lates  the  expression  of  mitochondrial  genes,  affecting  cell
proliferation and differentiation [64].
3.2. CyPA
CyPA  is  the  archetype  cyclophilin  member  and  is  in-
volved in multiple cellular processes such as protein folding,
intracellular trafficking, signal transduction, transcriptional
regulation, etc. CyPA is ubiquitously expressed in the cell,
although it can also be secreted into the medium in response
to  inflammatory  stimuli  such  as  hypoxia,  infection,  and
oxidative stress, among others [65]. Importantly, the secret-
ed form shows autocrine and paracrine properties by binding
to the CD147 cell surface receptor [66], also called basigin
and EMMPRIN (extracellular matrix metalloproteinase in-
ducer). This receptor seems to be expressed in neurons but
not in glial cells [67].CyPA shows pleiotropic biological ac-
tions in addition to protein folding and trafficking, such as it
is also related to cell activation, cardiovascular diseases, dia-
betes, chemotaxis, atherosclerosis, viral infections, drug re-
sistance, cancer, neurodegenerative diseases, aging, etc [65,
68-70].
Regarding their roles in the nervous system, CyPA has
been implicated in essential neuronal functions such as axon-
al transport, synaptic vesicle assembly, neuroprotective roles
against  abnormal  protein aggregation [71],  as  an auxiliary
factor for BDNF neuroprotective actions [72, 73], etc. CyPA
also performs neuroprotective responsibilities against both
oxidative stress [74] and ischemic events [67]. In line with
these observations, the direct injection of purified CyPA ex-
erts protective roles after brain injury [75], and it was also re-
ported that fibril formation in a cell-free system [76] and β-
amyloid toxicity in PC12 cells [77] were prevented by incu-
bation with recombinant CyPA. In the case of the cells, the
most likely reason for these effects is because CyPA acts as
a  scavenger  of  reactive  oxygen  species,  thus  attenuating
oxidative stress [77]. Clearly, these observations have impli-
cations in cases of Alzheimer’s disease and other neurogen-
erative diseases. Strikingly, it has recently been demonstrat-
ed that CyPA colocalizes with the Parkinson's disease (PD)-
associated protein α-synuclein and is also capable of interact-
ing with α-synuclein oligomers [78].
3.3. FKBP12
FKBP12 is involved in a high level of aggregation of α-
synuclein  and,  therefore,  in  Parkinson’s  disease  [79].  The
PPIase catalytic activity is required since site-directed muta-
genesis of Pro to Ala makes FKBP12 incapable to accelerate
the aggregation process in dendrites [80]. Accordingly, the
pharmacologic inhibition of FKBP12 with a non-immuno-
suppressive synthetic ligand (ElteN378) overturns the forma-
tion of those dendritic fibrillar structures and leads to the for-
mation  of  poorly  branched  molecular  assemblies  of  small
size [81], which is consistent with the above-mentioned ef-
fect on the aggregation of α-synuclein. On the other hand,
the  nature  of  the  putative  FKBP12-dependent  mechanism
that ultimately leads to Alzheimer’s disease tauopathies and
Lewy  Body  Dementia  still  remains  uncertain.  Thus,  even
though the dysregulation of the expression level of FKBP12
may lead to aberrant aggregation of proline containing pep-
tides, the consequent dysregulation of any cellular pathway
where FKBP12 may participate can also take place in paral-
lel. Nonetheless, it appears that FKBP12 is indeed related to
these diseases and emerges as a promising biomarker and po-
tential target for inhibitors in ongoing clinical trials [79, 82].
It is accepted that Alzehimer’s disease is the consequence of
the activity imbalance of various different proteins [83, 84].
In this regard, a disrupted expression of FKBP12 has been re-
ported  in  Alzheimer’s  disease  brain  samples,  where  a  re-
duced  expression  of  this  immunophilin  has  been  detected
[85].
3.4. Pin1
Another member of the immunophilin family that is relat-
ed  to  neurodegenerative  diseases  is  Pin1  (Peptidylprolyl
isomerase  Interacting  with  Nima-1).  It  is  a  unique  PPIase
from the perspective that  binds to specific  phosphorylated
proline-directed  serine  or  threonine  motifs  (pS/T-P)  [86].
Pin1 is highly abundant in the nervous system [87] and has
been related to Tau and β-amyloid stability [88, 89]. Accord-
ingly,  mice  lacking  the  expression  of  Pin1  develop  tauo-
pathies  and  experience  a  high  rate  of  the  loss  of  neurons
[90]. Pin1 binds Thr231-phosphorylated Tau and catalyzes the
transformation of cis-Tau to trans-Tau, allowing its binding
to microtubules [91]. Nevertheless, it has also been shown
that β-amyloid oligomers affect Tau regulation by Pin1 stim-
ulating  Tau  dephosphorylation  at  Thr231  [92].  Moreover,
Pin1  can  modulate  GSK3β leading  to  downstream regula-
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tion of Tau and β-amyloid. GSK3β is usually hyperactivated
in Alzheimer’s disease brains [93]. Therefore, it is not sur-
prising the association of deficient Pin1 activity with high
levels of Tau, leading to decreased degradation, elevated lev-
els of β-amyloid, and decreased GSK-3β inhibition. Interest-
ingly, it is thought that this phenomenon could be sufficient
to initiate a process leading to Alzheimer’s disease [59, 88,
89].
3.5. High molecular weight immunophilins
It is regarded that the biological actions of this group of
immunophilins  are  coupled  to  their  capability  to  interact
with HSP90 via TPR domains [94], such that the association
of both proteins forms a functional unit [48]. This may be
the case in Alzheimer’s  disease where FKBP52, FKBP51,
FKBP38,  FKBP37/Xap2,  and  CyP40  (see  Fig.  2)  are  in-
volved in its biology via a molecular mechanism that also in-
volves the HSP90/HSP70 heterocomplex. In addition to the
mandatory presence of the PPIase domain in this family and
the HSP90-binding TPR-domain, high molecular weight im-
munophilins may exhibit additional domains. The most fre-
quent  of  them  (especially  in  plant  immunophilins)  is  the
CBD  domain  (calmodulin-binding  domain).  In  mammals,
the CBD is present in FKBP38 and FKBP52. Even though it
is clear that the CBD domain interacts with Ca2+/calmodulin
and shows the capability to bind microtubules, its true bio-
logical  significance  still  remains  unknown.  It  was  first
thought that it can affect tubulin polymerization, but all mi-
crotubule polymerization assays with FKBP52 were carried
out in the presence of Ca2+-chelator such as EGTA, which
rules out calmodulin as the candidate molecule required for
this process [95, 96].
3.5.1. FKBP52
Some members of the TPR-domain subfamily have liai-
son  with  both  Tau  and  β-amyloid  proteins,  in  particular
FKBP52 [88, 97, 98]. This immunophilin has been shown to
be highly expressed in normal neurons of the hippocampus,
cortex,  and  basal  ganglia,  but  is  abnormally  low  in
Alzheimer’s disease brains [99]. This was particularly evi-
dent  in  the  frontal  cortex  of  all  17  studied  brains  as  com-
pared  to  control  brains.  Interestingly,  this  low  level  of
FKBP52 expression is accompanied by normal amounts of
its  specific  mRNA  level.  Therefore,  the  involvement  of
FKBP52 in pathological Tau expression and function is like-
ly.  In  this  regard,  it  has  been  demonstrated  that  FKBP52
binds  directly  to  Tau  and  is  capable  of  regulating  micro-
tubule dynamics [100]. In this regard, it has also been report-
ed that FKBP52 expression is inversely related to β-amyloid
toxicity in a Drosophila model [97], but the inverse effects
were also shown [101] for the effect of FKBP52 on the in
vitro oligomerization of a pathological P301L mutant of Tau
responsible for human tauopathy.
We have shown that FKBP52 is upregulated during neu-
ro-differentiation  and  also  in  regenerating  neurons  [102,
103]. This indicates a protective and a regenerative role of
this immunophilin. In an Alzheimer’s disease model in Dro-
sophila, mutations in the orthologue dFKBP59 exacerbated
both the expression levels and also the toxicity of β-amyloid
in transgenic flies overexpressing β-amyloid peptides [97].
It is interesting to emphasize that the authors demonstrated
that  the  overexpression  of  the  orthologue  dFKBP52  sup-
pressed  the  β-amyloid-induced  short  lifespan  and  reduced
levels of β-amyloid in the nervous system of the flies. In the
same study [97],  cells  stably transfected with  APP (HEK-
APP cells) were assayed, and a similar reduction of β-amy-
loid  peptides  was  observed.  These  observations  validate
those  made  in  the  Drosophila  model.
As stated above, human Alzheimer’s disease is probably
similar to most of the polygenic diseases, i.e. possibly result-
ing  from  an  imbalanced  expression  of  many  proteins.
FKBP52 may be included within this model since its expres-
sion  level  in  brain  tissue  from  people  who  had  died  of
Alzheimer’s disease is low when compared to normal brains
or  non-neurological  disease  brains  [98].  Decrease  in
FKBP52 expression may additionally have multiple conse-
quences in tauopathies, such as defects of axonal guidance
[104]  related  to  the  loss  of  its  regulatory  capacity  on  the
TPRC1 calcium channel, as well as destabilization of the mi-
crotubule network, which may lead to synaptic dysfunction
and neuronal death [95]. Another FKBP52 interacting pro-
tein is APP (Amyloid Precursor Protein), whose C-terminal
end also binds FKBP12 [105]. It has been demonstrated that
endogenous APP co-immunoprecipitates with FKBP52 in a
manner that is competed by FK506 [97], suggesting that the
PPIase domain of this immunophilin is required for the inter-
action. At present, whether the binding of FKBP52 to APP
disrupts the amyloidogenic management is still unclear and
needs to be resolved.
3.5.2. FKBP51
FKBP51 (encoded by FKBP5 gene) is a closely related
homolog of FKBP52 (encoded by FKBP4 gene) that is also
highly expressed in neurons, although it has been primarily
characterized as a member of the GR•HSP90 heterocomplex
[48, 94]. Actually, the relationship of FKBP51 with GR is
negative in the sense that the immunophilin is an inhibitor of
steroid  binding,  GR  transport  towards  the  nucleus  and
steroid-dependent transcriptional activity. Such a short feed-
back loop negatively regulates GR activity. FKBP51 is high-
ly  expressed  in  rodents’  brain  structures,  especially  in  the
hippocampus, amygdala, and the hypothalamic paraventricu-
lar nucleus, especially after stress stimuli or challenge with
glucocorticoids [106]. Furthermore, FKBP51 has also been
shown to be prominently upregulated in neurons of the dor-
sal horn in mice models of inflammatory pain.
The aggregation of Tau protein in the brain has been as-
sociated with a family of neurodegenerative diseases known
as tauopathies. FKBP51 forms mature chaperone complexes
with HSP90 that exert a strong effect on Tau degradation.
Consistently, Tau levels are reduced throughout the brains
of FKBP5–/– mice. Recombinant FKBP51 and Hsp90 syner-
gize to block Tau clearance through the proteasome, result-
ing in Tau oligomerization. Overexpression of FKBP51 in a
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Tau  transgenic  mouse  model  revealed  that  FKBP51  pre-
serves  the  Tau  stability,  a  phenomenon  that  worsens
Alzheimer’s disease pathogenesis.  It  also interacts with β-
amyloid  formation  [107,  108],  but  the  functional  role  of
such interaction has not been elucidated yet. FKBP51 has al-
so been characterized for its role in the regulation of Tau bi-
ology [109]. Thus, while FKBP51 overexpression preserves
Tau stability, FKBP51-KO mice show reduced levels of en-
dogenous Tau [107].
3.5.3. FKBP38
FKBP38 is a peculiar member of the immunophilin fami-
ly because, even though it possesses a diffuse sequence of
amino acids compatible with a PPIase domain, the constitu-
tive enzymatic activity is loosely conserved, although it can
be substantially  recovered in  a  Ca2+/calmodulin-dependent
manner [110]. FKBP38 does not bind the immunosuppres-
sive drug FK506 either [111]. It shows three TPR domains
through which FKBP38 interacts with HSP90. It is localized
in mitochondria and inhibits apoptosis by recruiting the an-
ti-apoptotic proteins Bcl-2 and Bcl-xL to the organelle. Al-
though FKBP38 is expressed in all  tissues,  it  is  especially
abundant in the brain and can be found in both neurons and
in  glial  cells.  It  has  been  observed  that  FKBP38  deficient
mice die soon after birth due to defects in neural tube clo-
sure, which is the consequence of unrestrained apoptosis. As
much as neuroectoderm organization fails during embryoge-
nesis, mice not only die soon after birth, but they also show
prominent malformations in the nervous system [112]. More-
over, the animals also show malformations of the cerebrum,
cerebellum, and dorsal root ganglia.
In  Parkinson’s  disease,  PINK1-regulated  mitophagy
events have been linked to the loss of dopaminergic neurons
in the substantia nigra, and it has been observed that the sus-
ceptibility  to  neuronal  apoptosis  during  mitophagy  is
markedly increased in FKBP38-deficient mice, suggesting a
protective role of this immunophilin in the development of
that neurodegenerative disease [112]. When FKBP38 is asso-
ciated with the small-like GTPase Rheb protein, the mTOR
signaling cascade is inhibited [113], which is regarded to be
a favorable defensive mechanism against Alzheimer’s dis-
ease [88, 114]. Thus, various stimuli that favor the develop-
ment and progression of the disease, for example, constant
augmented oxidative stress, can activate the mTOR pathway
enhancing  the  formation  of  β-amyloid  aggregates.  This  is
mostly due to the blockage of autophagy. In line with this,
the inhibition of mTOR cascade by rapamycin decreases the
accumulation  of  β-amyloid  and  ameliorates  the  cognitive
function in mouse models of Alzheimer’s disease [115], this
being an alternative and unconventional treatment.
3.5.4. CyP40
Cyp40 is a cyclosporine A binding immunophilin of 40-
kDa that has a PPIase domain and three TPR-domains. As
such,  it  is  an  HSP90-interacting  protein  that  was  first  de-
scribed as a co-chaperone bound to steroid receptor complex-
es  [116].  This  TPR-domain  immunophilin  was  shown  to
compete with FKBP52 for binding to HSP90, especially in
estrogen receptor and progesterone receptor heterocomplex-
es [117]. In contrast to its smaller partners CyPA and CyPD,
it is not a major mitochondrial factor strongly involved in im-
munosuppressive effects or in the activity of the mitochon-
drial  permeability  transport  pore.  Like CyPA [118],  it  has
been observed that CyP40 can also be involved in anti-apop-
totic mechanisms [119].
CyP40 is an immunophilin abundantly expressed in the
CNS, whose specific biological roles have begun to be eluci-
dated very recently. Interestingly, it has been reported that
CyP40 binds β-amyloid and regulates its import into mito-
chondria  [120].  Accordingly,  the  inhibition  of  Cyp40  was
found to be protective against the β-amyloid toxicity in both
whole mitochondria and neurons. Transduction of CyP40 in
a tauopathic brain reduced Tau oligomers and tangles, yield-
ing significant improvements in the overall neuronal health,
and mice also preserved cognitive functions. CyP40 decreas-
es both Tau fibril and oligomer accumulation in a transgenic
mouse tauopathy model and delivery of CyP40 to neurons
early in the pathogenic progression of the mouse model re-
sults in significant improvements in learning and memory as
assessed  by  radial  arm  water  maze  and  fear  conditioning
paradigms.
These observations suggest that CyP40 may be a poten-
tial  therapeutic  pharmacologic  target  for  the  treatment  of
tauopathies  and  other  amyloidogenic  disorders  [121].  Be-
cause it has been reported that upon cellular stress, HSP90
dissociates from CyP40 complexes [122], it may be speculat-
ed that the generation of certain situation of stress could in-
crease the pool of more catalytically active CyP40, a possi-
ble therapeutic alternative to activate this immunophilin and
inhibit the potential toxic effects of amyloid build-up.
3.5.5. Other Immunophilins
In addition to the better-studied group of immunophilins
described above, there are several other immunophilins that
show  a  relatively  good  expression  in  the  CNS,  such  as
FKBP133, FKBP65, FKBP63, FKBP25, FKBP23, FKBP19,
FKBP13, FKBP12.6 and FKBPL. Even though they are not
prolifically investigated in this tissue, some of these mem-
bers have been linked to neurodegenerative diseases, espe-
cially Alzheimer’s disease, such as FKBP133, FKBP65, and
PTPA [88]. It is known that FKBP133 (also named WAFL)
is  expressed  in  the  hippocampus,  cerebral  cortex,  and  pe-
ripheral  ganglia,  and  is  predominantly  localized  to  axonal
shafts,  and  also  associated  with  F-actin  in  growth  cones
[123].  Little  is  known about  the  properties  of  this  PPIase,
and to date, it has not been related in a direct manner to neu-
rological  diseases.  Nonetheless,  it  has  been  observed  that
FKBP133 deficient cells show delayed transport of endoso-
mal cargoes, which was observed in a model whereby this
immunophilin was found to be implicated in the transport of
early endosomes at the level of transition between microfila-
ment-based and microtubule-based movement [124],  play-
ing an important role in endocytosis and subsequent mem-
brane trafficking [125].
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FKBP63  (also  named  FKBP60  and  FKBP9)  has  been
suggested to play a role in prion spreading and degradation
[126].  Because  β-amyloid  and  tau  can  spread  in  a  prion
fashion [127], this may imply that FKBP63 could potentially
play a role in their propagation, particularly if it would be
considered that prions are thought to be initiating factors of
Alzheimer’s disease [128]. Recently, it has been suggested
that  this  immunophilin  promotes  malignant  behaviour  of
glioblastoma  cells  and  confers  resistance  to  endoplasmic
reticulum stress inducers [129].
PTPA (Phospho-Tyrosyl Phosphatase Activator) is a dist-
inctive PPIase that enhances the enzymatic activity of pro-
tein phosphatase-2A [130]. This is relevant for the phospho-
rylation  status  of  Tau  since  it  is  regarded  that  this  pro-
tein-phosphatase is mainly responsible for Tau dephosphory-
lation [131]. In Alzheimer’s disease, brain PTPA is down-
regulated, thus leading to the subsequent decreased activity
of protein-phosphates 2A and the elevated levels of Tau spe-
cies [132].
4. HEAT-SHOCK PROTEIN OF 90-kDa
4.1. Overview
The reader can find most of the properties of HSP90 on
protein aggregates in the sections where every involved pro-
tein is described. This is not surprising because HSP90 is the
gravity  centre  for  most  of  the  biological  responses  to  the
harmful effects  of  protein misfolding.  Nonetheless,  in this
section, we will summarize some general features of this car-
dinal chaperone.
This chaperone is the most abundant soluble protein in
the cell. In resting cells, HSP90 accounts for ~2% of the to-
tal amount of soluble proteins; it represents ~5% in several
cancer cell types and can reach up to 10% in cells or unicel-
lular  organisms  under  stress  [133].  It  shows  intrinsic  AT-
Pase enzymatic activity and functions as a hub protein capa-
ble of interacting with several proteins in oligomeric hetero-
complexes. Perhaps one of the most distinctive features com-
pared  to  other  chaperones  is  the  fact  that,  even  though
HSP90 can rescue aggregated and denatured proteins or pre-
vent protein denaturation, it functions as a refined sensor of
protein function. This means that HSP90 facilitates the bio-
logical  activity  of  properly  folded  client  proteins  that  al-
ready have a preserved tertiary structure. Thus, HSP90 re-
lates to various elemental cell functions such as the regula-
tion of the biological activity of key signaling proteins (s-
teroid receptors, protein kinases, ubiquitin ligases, cell cycle
regulators, transcription factors, etc.), the cytoplasmic trans-
port of soluble proteins, the translocation of client proteins
to organelles, and it can even act as an extracellular factor
with autocrine/paracrine-like properties [134].
4.2. The HSP90• Tau association
Compared  to  the  chaperones  described  above,  HSP90
shows high homology and structural characteristics with the
previously described mitochondrial protein TRAP1. Like the
other HSPs, HSP90 has a profound protective role in most
neurodegenerative diseases. It can interact and rescue aggre-
gates of amyloid, Tau, huntingtin, synuclein and prion pro-
teins. It forms complexes with other chaperones (detailed in
each individual section), but it  forms a special partnership
with HSP70. A good example of this functional association
is  the  fate  of  Tau,  which  is  defined  by  the  HSP70/HSP90
complex;HSP70 participates during the early folding path-
way and associates  with  misfolded  Tau and transfers  it  to
HSP90 for its further processing. Failure of this mechanism
leads to Tau degradation either by the ubiquitin-proteasome
system or by autophagy [135].
The region of the chaperone involved in the formation of
complexes with Tau shows a profound dip topography be-
tween amino acids 210 and 380, which comprises of a repeat
region of HSP90 [136]. In turn, the area of Tau involved in
the binding to HSP90 shows a large number of aromatic and
hydrophobic side-chains when compared to the N-terminal
and C-terminal domains. HSP90 shows a large binding site
for Tau equivalent to 106-Å long and 840-Å, which permits
several low-affinity contacts between the chaperone and the
client protein. The substrate-binding site on HSP90 shows
negatively charged amino acids that interact with the posi-
tively charged amino acids of Tau [137].
The functional coordination with other chaperones also
plays a key role in the interaction of HSP90 with Tau (and al-
so  other  clients).  Thus,  co-chaperones  such  as  CHIP  and
HOP (Hsp70 and Hsp90 organizing protein) act in a coordi-
nated fashion with both HSP90 and HSP70 [138], as well as
Aha1 (Activator of HSP90 ATPase-1), the Ser/Thr-phospha-
tase PP5, Cdc37 (Cell Division Cycle 37-kDa protein), p23,
etc., among the other HSP90 cochaperones that help in the
proper  folding  mechanism of  the  client  protein  or  in  their
degradation mechanism [135, 139]. The consequences of th-
ese associations follow two possible ways: (a) reducing the
transition time for HSP90•ADP, a chaperone isoform that en-
hances  the  client  protein  release,  and  (b)  stabilizing  the
HSP90•ATP isoform attached to the client protein. The lat-
ter is the case for HSP90•Tau complexes that recruit PP5 to
dephosphorylate  the  highly  phosphorylated  forms  of  Tau,
thus favoring its proper folding. However, when HSP90•Tau
complex associates other TPR-domain factors such as CHIP,
the Tau fate ends in its ubiquitination followed by proteaso-
mal degradation [138].
Because both terminal domains of HSP90 are involved
in  the  intrinsic  ATPase  activity  of  the  chaperone,  several
small molecules have been designed and assayed as inhibi-
tors of the protein folding cycle [140], and they are the sub-
ject of pharmacological studies to affect Tau aggregates by
targeting HSP90. The inhibition of the ATPase activity of
HSP90 with the ansamycin geldanamycin resulted in a signi-
ficant  increase  in  levels  of  soluble  Tau  and  also  micro-
tubule-associated  Tau  but  decreased  levels  of  Tau  aggre-
gates [141]. The N-terminal domain inhibitor EC102 was ad-
ministered to transgenic mice causing HSP90 inhibition and
the subsequent degradation of aberrant phosphorylated Tau
species [142]. In contrast to the ATPase inhibitors that bind
the C-terminal end of HSP90, which are not capable of af-
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fecting HSF1 activity, those that associate with the N-termi-
nal end favour the activity of HSF1, and therefore, the ex-
pression of other chaperones is also induced. In turn, higher
expression of chaperones is effective for decreasing the lev-
els of aggregated proteins. In this regard, it  is our opinion
that controlling HSP90 function itself is indeed a challeng-
ing issue too rife with liabilities to pursue in the clinic due to
the pleiotropic actions of this chaperone. Perhaps, an alterna-
tive approach to controlling co-chaperones may have greater
potential to confer specificity to a particular disease target
through HSP90. This is because co-chaperones modulate sig-
nificantly fewer processes than the parent chaperone and it
becomes more probable to avoid undesirable side-effects. In
other words, HSP90 co-chaperones hold promise for target-
ing  β-amyloid,  α-synuclein  and/or  Tau  more  specifically
than  through  HSP90  alone.
5. FKBPs AND RECEPTOR TRAFFICKING
5.1. The transportosome model
Both  TPR-domain  immunophilins,  FKBP51  and
FKBP52, were first characterized as members of the steroid
receptor•HSP90 heterocomplex [143, 144]. The subsequent
discovery that the dynein/dynactin motor protein complex as-
sociates  with  FKBP52 [145]  and  also  with  other  TPR-do-
main proteins belonging to the HSP90-based complex such
as CyP40 and PP5 [146] has led to analyse the composition
of the steroid receptor complex [147-150] and other soluble
factors  [151-154].  The  evidence  showed  that  the  dynein-
based motor complex binds to FKBP52 via the PPIase do-
main  [145,  146,  155],  a  property  that  is  not  shared  by
FKBP51 [156]. Importantly, FKBP51 is mostly found to be
associated with the receptor  in  the ligand-free state  and is
functionally  replaced  by  FKBP52  upon  steroid  binding
[157-159].
As a consequence of those studies, a novel model for the
mechanism of action of the receptor•hormone complex was
proposed [160] and is summarized in Fig. (3). The receptor
is actively transported towards the nucleus on cytoskeletal
tracks  by  a  chaperone  machine  named  ‘transportosome’,
which is assembled by a dimer of HSP90 and one molecule
of HSP70, one molecule of p23, and one TPR-domain im-
munophilin [161]. This concept radically modified the clas-
sic model posed decades ago for the mechanism of activa-
tion of steroid receptors, which stated that HSP90 must be re-
leased from the complex upon steroid binding to “detach”
the receptor from its cytoplasmic anchorage sites.
It should be pointed out that, regardless of their primary
subcellular localization, these receptors and almost most sol-
uble proteins are not necessarily confined to a particular cell
compartment in a static manner, but they continuously shut-
tle  between  cytoplasm  and  nucleus  [159,  160,  162,  163].
Thus, the heuristic classic dogma was replaced by a model
where the receptor•(Hsp90)2•FKBP52•dynein complex medi-
ates  the  cytoplasmic  transport  and  also  translocates  GR
through the nuclear pore. Therefore, the GR•chaperone hete-
rocomplex is just dissociated in the nucleoplasmic compart-
ment  rather  than  in  the  cytoplasm,  such  that  the  receptor
dimerizes and is activated to function as a transcription fac-
tor. Importantly, all these mechanistic steps were experimen-
tally tested for each individual step [155, 160, 164-166].
5.2. GR Nuclear Translocation and Alzheimer’s Disease
Because hypercortisolemia is a common feature in many
neurological  disorders,  the  modulation  of  the  GR  nuclear
translocation in neurons by FKBP51 and FKBP52 has been
linked to the development of depressive disorders [167] and
is  considered a  risk  factor  to  develop Alzheimer’s  disease
[168]. Glucocorticoid hormones are synergized by excitato-
ry amino acids (for example, glutamate) favouring the dis-
ruption  of  the  hypothalamic-pituitary-adrenal  (HPA)  axis.
This over-stimulation and/or modifications of the GR proper-
ties are neurotoxic, a phenomenon particularly notorious in
limbic  structures  such as  amygdala,  prefrontal  cortex,  and
hippocampus [169]. It is accepted that chronic stress and sub-
sequent repeated situations of stress affect the dendrites of
neurons located in the CA3 region of the hippocampus lead-
ing to neuronal atrophy and suppression of neurogenesis in
dentate gyrus neurons [170]. This loss of synaptic plasticity
represents  a  cardinal  situation  of  the  Alzheimer’s  disease
syndrome and can be related to cognitive decline that is char-
acteristic of these patients [171].
As mentioned above, depressive disorders are linked to
mechanisms that develop Alzheimer’s disease, although the
actual switch is still poorly understood. Nevertheless, some
evidence indicates that one of the possible reasons may be
the dysregulation of the HPA axis that accompanies the high
plasma levels of glucocorticoid steroids and impairment of
the GR-dependent signaling response. One common and old
evidence of such dysregulation is the functional failure for
cortisol suppression following a dexamethasone challenge,
which reflects the inability of the HPA axis to preserve the
hormonal homeostasis [172, 173]. Interestingly, the activity
of GR can be indirectly regulated by other factors that may
be used for therapeutic purposes. For example, it was report-
ed that in murine models of spinal cord injury, the activation
ADORA2A, also known as adenosine A2A receptor, mim-
icked the effects of GR activation in attenuating neuronal da-
mage [174], and its pharmacologic inhibition reversed mem-
ory deficits by the reestablishment of the HPA axis feedback
[175]. It is regarded that A2A receptor activation enhances
susceptibility to glucocorticoids by favoring GR nuclear ac-
cumulation and consequently GR down-regulation. The inhi-
bition  of  A2A  receptor  impacts  GR  nuclear  translocation
and transcription and represents a novel therapeutic strategy
to ameliorate cognitive deficits in neuropsychiatric disorders
by precluding GR action [168]. As a matter of fact, A2A re-
ceptor  has  been  found  upregulated  in  the  forebrain  of
Alzheimer’s disease patients [176], and glucocorticoids have
been shown to up-regulate both Tau and β-amyloid patholo-
gy, which may represent a secondary mechanism by which
immunophilins such as FKBP52 are known to be involved
in Alzheimer’s disease mouse models [177].
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Fig. (3). Active retrotransport of GR is mediated by the HSP90•FKBP52•Dynein complex, a functional unit also referred to as “transporto-
some”. Unliganded GR forms cytosolic complexes with a dimer of HSP90 and one molecule of HSP70, the cochaperone p23, and FKBP51.
Steroid (H) binding favors the exchange of FKBP51 by FKBP52, an immunophilin that interacts with the dynein/dynactin motor complex
that powers GR retrotransport on cytoskeletal tracks. Note that the entire heterocomplex passes through the nuclear pore complex (NPC) and
is dissociated in the nuclear compartment, where GR dimerizes. (A higher resolution / colour version of this figure is available in the elec-
tronic copy of the article).
Another unexpected regulator of the GR function is mela-
tonin  (N-acetyl-5-methoxytryptamin),  an  endogenous  hor-
mone produced in the brain by the pineal gland. Its produc-
tion  decreases  during  aging  and  also  in  patients  with
Alzheimer’s  disease  [178].  Treatments  with  melatonin
showed effective protection of neuronal cells from β-amy-
loid toxicity and attenuated Tau hyperphosphorylation. How-
ever, the exact mechanism is not known yet, but it is likely
to  assume  that  its  antioxidant  and  anti-amyloid  properties
may be involved.  This  hormone not  only  impairs  amyloid
generation but also arrests the formation of amyloid fibrils
by interaction with the structure of the β-amyloid. An effect
on the GR-dependent mechanism cannot be ruled out since
it has also been documented that melatonin has antagonistic
action on GR-mediated effects, a mechanism that involves
the inhibition of the dissociation of HSP90 from the recep-
tor,  disruption  of  the  transportosome  machinery  and  the
consequent  retention  of  the  GR  in  the  cytoplasm  [179].
5.3.  Transportosome  Inhibition  Leads  to  GR Aggrega-
tion in Axons
The HSP90 inhibitor  geldanamycin  prevents  the  retro-
transport of agonist-preloaded GR due to the disruption of
the chaperone function [180]. As it was shown in fibroblast
cells,  the  treatment  of  neurons  with  geldanamycin  slowed
down but did not entirely block the retrograde movement of
GR in the cell body, i.e. with time (more than one hour ver-
sus 10 min in normal conditions), GR becomes nuclear any-
way. However, in neurites, the GR transport towards the nu-
cleus is blocked by the HSP90 inhibitor [181]. Interestingly,
the receptor collects in globules located periodically along
the neurites (Fig.4). When geldanamycin is withdrawn, the
GR exits these globules and movement towards the nucleus
continues. If geldanamycin is maintained in the medium, the
GR is targeted to degradation via the proteasome. This was
evidenced because CHIP (C-terminus of HSC70-interacting
protein),  the  E3-ubiquitin  ligase  for  the  GR  [182],  also
moves  into  those  globules  by  a  glucocorticoid-dependent
mechanism  when  cells  are  treated  with  geldanamycin
(Fig.4). Consequently, in the neurites of cells exposed contin-
uously to the HSP90 inhibitor, the ubiquitin ligase that initi-
ates  the  process  of  GR degradation  by  proteasome  moves
with  the  receptor  into  centres  where  protein  degradation
takes place [181]. HSP70, which is also required for GR pro-
teasomal  degradation,  is  also  recruited  to  the  same  struc-
tures. All this process is inhibited by MG132, a proteasome
inhibitor. A possible explanation for the periodic location of
these  ‘GR globules’  along the  neurites  may lie  in  the  fact
that the receptor accumulates in protein-quality control cen-
tres  containing  the  machinery  (for  example,  CHIP  and
HSP70) required for proteasomal degradation, and it local-
izes periodically along the neurite. Because HSP90 is also
capable of interacting with cytoskeletal proteins [183], it can
also be possible that GR aggregates due to an alteration in
the cytoskeletal network.
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Fig. (4). HSP90 inhibitors aggregate GR in neurites. GFP-GR local-
izes in the cell body and neurites of neurons not exposed to steroid
(a), whereas it was fully accumulated in the nucleus 30 min after
the addition of 100 nM dexamethasone (b). When the cells were
preloaded on ice with a steroid (to permit steroid binding, but not
the nuclear translocation), and then incubated at 37oC in the pres-
ence of 0.1 μM geldanamycin, the GFP-GR pool of the cell body
rapidly moved into the nucleus, but not the receptor present in long
neurites  (c).  Here,  GFP-GR  formed  aggregates  that  co-localized
with CHIP (d) the E3-ligase of GR, and also HSP70 (not shown).
Panel  €  shows  the  colocalization  of  GFP-GR  (green)  and  CHIP
(red). Bar= μ10 m. (A higher resolution / colour version of this fig-
ure is available in the electronic copy of the article).
5.4. CHIP, HSPs and Dynein Motors
The  excessive  formation  of  protein  aggregates  and/or
their fibrillar structures is generally observed in at least thir-
ty different human diseases, most of them being neurodegen-
erative diseases [184, 185]. In highly polarized cells such as
neurons,  the  axonal  transport  of  organelles,  vesicles,  mR-
NAs, signaling proteins and transcription factors to and from
the neuronal cell body is a critical issue that requires the co-
ordinated action of motor proteins. Therefore, it is not sur-
prising that impairing axonal transport adds to both the initia-
tion and progression of several neurodegenerative diseases
[186, 187].
As  commented  in  the  previous  section,  CHIP  is  a  key
neuronal  E3-ligase  responsible  for  proteasome  substrate
recognition in the case of damaged or aberrantly unfolded
proteins [138]. Similar to the case of the GR aggregates de-
scribed in Fig.4, poly-Q isoforms of the androgen receptor
(AR) are also targeted to proteasomal degradation via CHIP
[188]. The glutamine tract encoded by the AR gene compris-
es between 9 and 37 residues, but there are pathological ex-
pansions to 38 or more glutamines. This causes SBMA (Spi-
nal  and  Bulbar  Muscular  Atrophy),  also  known  as
Kennedy’s  disease,  a  progressive  neuromuscular  disorder
that affects only men [189]. It is characterized by AR aggre-
gation,  especially  in  spinal  cord motoneurons and skeletal
muscles, induced by the presence of androgens. Therefore,
the immunoadsorption of poly-Q AR is accompanied by co-
immunoadsorption of HSP90, p23, and the HSP90-binding
immunophilins  FKBP52 and  PP5  and  the  dynein/dynactin
motor  complex  [188],  consistent  with  the  entry  of  poly-Q
AR into aggregates as trafficking complexes. In agreement
with this observation and like the case above described for
GR, HSP90 inhibitors promote proteasomal degradation of
the  AR [190,  191]  and ameliorate  poly-Q-mediated  motor
neuron  impairment  in  mouse  models  [191,  192].  Like  the
case of the GR, HSP70 also co-stains with ubiquitin and pro-
teasome components.
Notably, HSP90 and HSP70 play opposing roles in the
triage of misfolded proteins. Thus, HSP90 stabilizes proteins
in a near-native state, protecting them from degradation. In
contrast, when the protein is greatly misfolded to be stabil-
ized  by  HSP90,  HSP70  facilitates  its  ubiquitination  by
chaperone-dependent E3 ubiquitin ligases, such as CHIP. In-
terestingly,  the  chaperone  BAG3  interacts  with  HSP70  in
complexes with CHIP and these polyubiquitinated substrates
[193]. When this heterocomplex commands aggresome com-
plexes, the direct retrograde transport of misfolded proteins
occurs on microtubules towards the MTOC, and those aggre-
gated  complexes  that  were  sequestered  in  these  misfolded
structures become cleared by a different system rather than
by the proteasome, i.e. the CHIP•HSP70•BAG3 complex tar-
gets poly-Q AR to degrade the lysosome by chaperone-as-
sisted selective autophagy [194, 195]. Both HSP90 inhibi-
tors and HSP70 ligands such as VER-155008 [196] enhance
this  activity.  Taken together,  the evidence provides strong
encouragement  for  the  sustained  development  of  small--
molecule  modulators  of  the  HSP90/HSP70  chaperone
machinery  as  a  potential  therapeutic  approach.
In  cases  of  human  Alzheimer’s  disease,  the  level  of
CHIP expression in the brain is inversely proportional to the
degree  of  Tau  protein  aggregation  [197].  In  a  transgenic
mouse model of Alzheimer’s disease, it was also shown that
the  accumulation  of  β-amyloid  reduced  the  expression  of
CHIP, whereas the level of Tau protein increased simultane-
ously [198]. Conversely, the restoration of CHIP expression
could rescue the normal level of Tau. Moreover, CHIP is al-
so able to interact with APP and, in certain contexts, it can
accelerate  the  removal  of  β-amyloid  and  therefore  protect
cells  against  proteotoxicity  [199],  following  a  mechanism
where the effects of CHIP, HSP70 and HSP90 are coopera-
tive.  All  these  observations  highlight  the  critical  role  of
CHIP  and  HSPs  in  Alzheimer’s  disease,  Parkinson’s  dis-
ease, Lewy’s Body Disease, prion or huntingtin pathologies.
Table  2  summarizes  the  properties  of  all  HSPs,  im-
munophilins, and other molecular chaperones discussed here
that are involved in the biology of aggregated proteins re-
sponsible  for  neurodegenerative  diseases  [107,  135,  195,
200-202].
12   Current Drug Targets, 2021, Vol. 22, No. 00 Daneri-Becerra et al.
Table 2. Chaperones and co-chaperones related to neurodegenerative diseases.
Protein Biological functions Main Localization Diseases* References
HSP90
Protein folding, affords functional activity to clients, degrades P-Tau, in-
creases Tau solubility, amyloid fibril formation, α-synuclein vesicle
binding







TRAP1 Mitigates toxicity of α-synuclein, Prevents the formation of fibrils, Regu-lates CyPD
Mitochondrial matrix, Partially cyto-
solic PD, AD? [33, 34, 38, 39]
HSP70 Mitochondrial import of proteins, Tau turn-over (increases degradation),Protein folding
Ubiquitous, mostly cytoplasmic, Ex-
tracellular AD, PD, HD [24, 26-29]
HSP60 Folding of mitochondrial matrix proteins, Hypomyelination 80%: Mitochondrial 20%: Cytoso-lic, ER, Peroxisomes; Extra-cellular
ALS, BHLD,
AD, SPG13 [12, 15-18]
HSP27
Averts filament degeneration, Increases dephosphorylated Tau levels,
Restoration in the amyloid plaque and tangle formation, Prevention of
fibril formation and α-synuclein aggregation.




CyPA Prevents abnormal protein aggregation, fibril formation, amyloid toxici-ty, and ROS damage; Stabilizes a-synuclein




CyPD Regulation of mitochondrial permeability transition pore, Apoptosis,Excitotoxicity Mitochondria
AD, HD,
ALS, KD [59-63]
Pin1 Influences Tau and β-amyloid stability, Can restore the functional activi-ty of P-Tau Nucleoplasm, cytosol AD, Tauopathies [88-91]
FKBP12 High level of aggregation of α-synuclein Cytoplasm PD, AD, LewyBody Dementia [79-81]
FKBP38 Inhibits apoptosis by recruitment of Bcl2 to mitochondria, Decreases β-amyloid levels Mitochondria PD, AD [112, 115]
FKBP51 Prevents Tau degradation enhancing neuro-toxicity, Interacts with β-amyloid (function?) Nucleus, cytosol and mitochondria AD, Taupathies [108, 109]
FKBP52 Promotes Tau oligomerization; protects against β-amyloid toxicity Nucleus, cytosol AD [88, 97, 98]
FKBP63 Prion spreading and degradation ER, mitochondria Prion Disease, AD? [126, 128]
CyP40 Protects against β-amyloid toxicity, Reduces Tau oligomers and tangles Cytosol, nucleus AD [120, 121]
CHIP Targets poly-Q AR for degradation, Prevents Tau aggregation Cytoplasm, nucleus SBMA, KD, AD [189, 191,193, 196]
PTPA Protects against β-amyloid toxicity Nucleus, cytoplasm AD [131, 132]
(*) AD: Alzheimer’s Disease, PD; Parkinson’s Disease; HD: Huntington’s Disease; KD: Kennedy’s Disease; ALS: Amyotrophic Lateral Sclerosis; SBMA: Spinal and Bulbar Mus-
cular Atrophy; BHLD: Brain Hypomyelination Leukodystrophy; SPG13: Hereditary Spastic Paraplegia; ?: Uncertain/To be demonstrated.
6.  MITOCHONDRIAL  TRAFFICKING  OF  TPR-DO-
MAIN IMMUNOPHILINS
The  presence  of  immunophilins  in  mitochondria  is  a
field recently developed. The biological functions of these
proteins in the organelle are poorly understood, and mostly,
they  are  subject  to  speculations  and  hypothesis  based  on
what  is  known  for  ‘regular’  immunophilins.  Nonetheless,
the most common feature described for all of them in mito-
chondria relates to their participation in mechanisms of apop-
tosis.
6.1. Mitochondrial FKBP38
FKBP38, FKBP51 and CyPA have been described in the
mitochondria of neurons, but only FKBP38 shows a known
mitochondrial localization signal that justifies this location
[203]. The mitochondrial localization of FKBP38 has been
associated with anti-apoptotic actions due to its capability to
recruit the antiapoptotic factor Bcl2 to the organelle. This im-
munophilin also shows the capability to translocate to the en-
doplasmic reticulum. Thus,  when the human neuronal cell
line SH-SY5Y is exposed to a mitochondrial uncoupler such
as  carbonylcyanide-m-chlorophenylhydrazone,  mitochon-
drial membrane depolarization is triggered, and the relative
abundance of most mitochondrial proteins decreases in paral-
lel  to  the  progression  of  mitophagy  [204].  However,  the
amounts of FKBP38 and Bcl-2 are not down-regulated, de-
monstrating that not all mitochondrial proteins are necessari-
ly degraded during mitophagy. Actually, FKBP38 leaves mi-
tochondria  and  resides  in  the  endoplasmic  reticulum.  The
physiological  relevance  of  such  translocation  during  mi-
tophagy lies in the fact that it seems to be a requirement to
trigger anti-apoptotic mechanisms rather than being responsi-
ble for mitophagy itself. This is supported by the fact that mi-
tophagy also occurs in FKBP38-deficient cells [112, 204].
Neuronal FKBP38 has a Ca2+/calmodulin-stimulated PPIase
activity that results in being essential for FKBP38–Bcl-2 in-
teraction to occur, Bcl-2 being a regulator of the transcriptio-
nal  activity  of  several  other  factors  such  as  NF-κB,  AP1,
CRE  and  NFAT  [205].  It  has  also  been  associated  with
calcineurin  and  p53,  possibly  modulating  their  function
[206]. In short, FKBP38 indirectly regulates the activity of
those factors involved in the apoptotic response and repre-
sents one of the first examples of a cofactor-regulated PPI-
ase.  This  activity  participates  in  Bcl-2-mediated  apoptosis
control  and  might  provide  the  cellular  mediator  of  neu-
rotrophic  effects  of  neuroimmunophilin  inhibitors.
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6.2. Mitochondrial FKBP51
FKBP51 has always been considered a cytosolic soluble
protein. Recently, it was unexpectedly detected in mitochon-
dria [207]. This localization is not dependent on the cell type
since it was observed in neuroblastoma cells, hippocampal
neurons, glial cells, adipocytes, fibroblasts, etc. Associated
with  this  subcellular  localization  (which  represents  more
than 50% of the cellular pool), FKBP51 shows antiapoptotic
actions.  Thus,  its  overexpression  stabilizes  the  mitochon-
drial  membrane  depolarization,  whereas  its  knock-down
makes mitochondria more sensitive to harmful stimuli [207].
The mitochondrial localization of FKBP51 in normal resting
cells  becomes  nuclear  upon  the  onset  of  stress  situations.
Thus, FKBP51 translocates rapidly (15–30 min) to the nu-
cleus, where it is thought to play anti-apoptotic roles. Such
nuclear  localization  is  rapidly  reversed  when  the  stimulus
ceases.  It  has  also been documented that  during fibroblast
differentiation into adipocytes, FKBP51 abandons mitochon-
dria  and  migrates  to  the  nucleus  with  a  PKA-dependent
mechanism  [208].
Interestingly,  mitochondrial  FKBP51 was found in  the
GR•HSP90 mitochondrial complex, its biological effect be-
ing unknown to date [207]. However, it is accepted that mito-
chondrial GR drives the expression of mitochondrial genes
[209, 210]. Therefore, FKBP51 may play a similar inhibito-
ry  role  as  that  described  for  the  nuclear  receptor,  which
should lead to antiapoptotic actions. When cells were treated
with dexamethasone, Bax accumulated in mitochondria and
became associated with Bak, Bim, Bcl-xL [211]. Moreover,
cytochrome c and active caspases were detected, indicating
that during the early steps of glucocorticoid-induced apopto-
sis, the mitochondrial GR plays a crucial role.
These observations should be evaluated within the con-
text of the role of glucocorticoids in the dysregulation of the
HPA axis, the classic inhibitory action of FKBP51 on GR-
dependent response, and the consequent development of neu-
rodegenerative  diseases.  Importantly,  the  translocation  of
FKBP51  to  nuclei  concentrates  almost  the  entire  cellular
pool of the immunophilin in the nuclear compartment, and
colocalizes with GR. In cortical neurons, the mitochondrial
translocation of GR is followed by a series of events that ex-
acerbate mitochondrial oxidations in a time- and dose-depen-
dent fashion [212, 213]. The biological relevance relates to
the generation of ROS and subsequent neurodegeneration ob-
served  after  chronic  exposure  to  glucocorticoids.  In  other
words,  an  inappropriate  response  to  these  hormones  may
contribute  to  the  pathogenesis  of  Alzheimer’s  disease  and
Parkinson’s disease.
6.3. Mitochondrial CyPA
In contrast to the group of TPR-domain immunophilins,
CyPA (also named CyP17), the small archetype of the cy-
clophilin  subfamily,  does  not  interact  with  HSP90.  CyPA
lacks  TPR-domains  (Fig.2).  Actually,  its  full  structure  is
limited to the PPIase domain. We have recently evidenced
by confocal microscopy and biochemical fractionation that
CyPA is also a mitochondrial factor [214].  Comparable to
FKBP51, CyPA also abandons mitochondria upon the onset
of stress stimuli and concentrates in the cell nucleus in a rev-
ersible manner, although its nuclear translocation rate is rela-
tively slower than that of FKBP51 (t0.5 of ⁓2 h versus 15-30
min). Standard assays showed that the overexpression of Cy-
PA in N2a neuroblastoma cells favoured cell survival when
N2a cells were exposed to harmful stimuli, which normally
leads to apoptosis. Interestingly, it has also been document-
ed  that  CyPA  directly  interacts  with  p23  [158],  a  small
acidic Hsp90-cochaperone that has already been evidenced
to show antiapoptotic action per se [215]. The association of
both factors, CyPA and p23, enhances the antiapoptotic ef-
fect  when  they  are  assembled  in  a  functional  unit  whose
high level of expression plays a significant role in cell survi-
val [214]. This observation may explain the observed effects
in vivo and in vitro against oxidative stress and ischemia--
like situations, and the putative beneficial action of the spe-
cific p23 ligand genduin, which has recently been proposed
as a non-conventional therapeutic agent for Parkinson’s dis-
ease [216].
7. HSF1 AND MITOCHONDRIAL RESPONSE
The expression of both HSPs and immunophilins is un-
der the command of the Heat-Shock Factor (HSF), a primari-
ly  cytoplasmic  transcription  factor  bound  to  a  similar
HSP90-based heterocomplex as that described for steroid re-
ceptors. There are various isoforms of HSFs (namely HSF1,
HSF2, HSF3, HSF4, HSF5, HSFXs and HSFYs,), HSF1 be-
ing the best characterized and commonly expressed among
vertebrates [217], whereas invertebrates express only a sin-
gle HSF [218]. Among the mammalian HSFs, HSF1 is the
master regulator of HSP expression, although HSF2 can also
hetero-trimerize  with  HSF1.  HSF1  is  cytoplasmic  in  its
monomeric form, which is kept inactive in the cytoplasm by
the  HSP90 protein  complex  [217].  Upon exposure  to  pro-
tein-damaging stress, it is thought that the HSPs are diverted
to the newly misfolded proteins, allowing the HSF to translo-
cate to the nucleus as homotrimers. It binds to Heat Shock
Element  sequences  in  the  promoters  of  genes  encoding
HSPs  to  turn  on  transcription  [217].
There is consensus to affirm that the HSF1shows protec-
tive action against neuronal death in diverse models of pro-
teinopathic neurodegenerative diseases. Accordingly, the HS-
F1 knock-down favours the neuropathological effects of tox-
ic  misfolded  proteins  [219],  whereas  its  overexpression
shows protective effects [220]. In line with these observa-
tions, the degradation of HSF1 in neurons contributes to mi-
tochondrial dysfunction and synaptic deficits [221, 222]. Ac-
cordingly, it has been reported that in Huntington’s disease,
HSF1 is abnormally degraded by the sequential action of in-
appropriately up-regulated CK2α’ (Protein kinase CK2 al-
pha prime) and Fbxw7, an E3 ligase [222]. In turn, this leads
to mitochondrial dysfunction due to a deficient response to
stress of molecular chaperones and immunophilins. Actual-
ly, the major role of HSF1 in mitochondrial activity was re-
ported in cardiomyocytes of HSF1-/- mice, which showed in-
creased overloading of calcium and exacerbated production
of  ROS  that  cause  mitochondrial  permeability  transition
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pore  to  open  [223].  Such  mitochondrial  dysfunction  con-
tributes to creating an imbalance of potential redox homeos-
tasis leading to oxidative damage, not only in Huntington´s
disease, but also in Alzheimer’s and Parkinson’s disease pa-
tients [224]. In the brain, this oxidative stress causes damage
that contributes to neuronal loss and formation of protein ag-
gregates. Thus, similar mechanisms have been proposed for
other neurodegenerative diseases such as Kennedy’s disease
and Prion disease, where the disruption of the normal HS-
F-HSP  functional  axis  also  leads  to  the  accumulation  of
harmful protein aggregates that  interfere with intracellular
trafficking.
Among  all  the  neuro-degenerative  diseases,  Hunting-
ton’s disease is perhaps the most sensitive to mitochondrial
dysfunction  due  to  regulation  of  HSF1  by  CK2α’  and
Fbxw7 E3 ligase described above. The decreased HSF1 lev-
els and the inability to resolve protein aggregates are exacer-
bated, thereby contributing to increased proteotoxicity, neu-
ronal dysfunction and death. Moreover, axonal trafficking is
greatly affected due to the particular  scaffolding nature of
the protein huntingtin that interacts with both kinesin-1 and
dynein motors, as well as over four hundred other proteins,
many  of  which  are  active  in  microtubule-based  or  act-
in-based transport [225]. Thus, the transport of key vesicles
is affected carrying BDNF (Brain-Derived Neurotrophic Fac-
tor),  GABA receptors,  precursors  of  synaptic  vesicles,  the
amyloid precursor protein, VAMP7 (involved in the fusion
of  transport  vesicles  to  their  target  membranes),  Rab  pro-
teins, protein-RNA complexes, autophagosomes, lysosomes
and  endosomes  [187].  Among all  these  cargoes,  BDNF is
perhaps the most critical due to its role in the health of the
cortico-striatal neuronal circuit, the primary site of degenera-
tion in the disease []. Striatal neurons are greatly dependent
on the trophic stimulation of corticostriatal afferents. Thus,
the inefficient stimulation by BDNF causes neurodegenera-
tion.
CONCLUSION AND FUTURE PERSPECTIVES
Mitochondrial HSPs and immunophilins are vital players
in mitochondrial function and consequently neuron function
and survival. They regulate cardinal events ranging from pro-
tein synthesis, protein folding, protein transport, ATP pro-
duction, reactive oxygen species production and cell homeos-
tasis. Failure in their key roles is likely an essential compo-
nent that worsens other deficiencies of the cell. Their expres-
sion and function are vital to participate in the natural aging
process and progression of neurodegenerative and metabolic
diseases that affect the ‘mitostasis’. Although there are sever-
al studies on the role of the GR in regulating the stress re-
sponse, little is known about its potential participation in mi-
tochondrial responses. Several studies have advanced our un-
derstanding of both the structural and functional regulation
of  this  receptor  by  HSP90-based  oligomeric  complexes.
Nonetheless, there is still much to learn about the in vivo reg-
ulation of  GR signaling by HSP90 cochaperones and how
the intracellular feedback loops and the major HPA axis of
the whole body are interconnected. This is particularly true
for  PPIases,  which  are  a  unique  family  of  protein  chaper-
ones that began to be considered in this aspect just a short
time ago.  Therefore,  modulating  the  activity  of  these  pro-
teins through specific drugs may restore the normal process-
ing of, for example, β-amyloid fibrils or Tau aggregation to
non-pathogenic  states,  or  even  better,  prevent  such  patho-
genic processing that leads to neurodegeneration.
In addition to their natural roles in assisting protein fold-
ing, HSPs have other functions like the regulation of protein
degradation and signalling pathways, especially those depen-
dent on the assistance of HSP90. Therefore, the potential use
of  drugs  targeting  these  chaperones  is  a  likely  pharma-
co-therapeutic  alternative.  For  example,  it  was  shown  in
vivo in a rat model where the animals were injected with a
β-amyloid peptide in the CA1 area of the hippocampus, and
then treated orally with 17-(allylamino)-17-demethoxy-gel-
danamycin (17-AAG) [226]. The encouraging results demon-
strated that immediate neuronal damage generated by the ac-
cumulation of β-amyloid aggregation was depurated by the
treatment,  which showed a  rapid  induction of  endogenous
HSP90 and HSP70 and great improvement in the cognitive
capabilities of the animals. The inhibition of HSP90 could
be a useful pharmacological tool in cases of Alzheimer’s dis-
ease to counteract the aggregation of hyper-phosphorylated
Tau.  The  disadvantage  is  that  geldanamycin  itself  cannot
cross  the  blood-brain barrier  [227],  although more perme-
able and less toxic derivatives such as 17-AAG and 17-D-
MAG could be an alternative; they are difficult to formulate,
have  limited  oral  availability,  or  have  caused  varying  de-
grees  of  hepatotoxicity  in  clinical  cancer  trials  [228].  The
search  of  HSP90  inhibitors  in  neurodegenerative  diseases
could benefit from clinical trial studies regarding anti-cancer
treatments.
Because chaperones are highly associated with the can-
cer field and neurodegenerative diseases, an alternative thera-
peutic approach could be the thermal treatments against can-
cer. Thermotherapy is a relatively novel treatment that uses
heat  in  a  targeted way to  generate  hyperthermia in  the  tu-
mour.  This  makes  more  effective  conventional  treatments
such as radiotherapy, presumably due to the positive influ-
ence of the induced chaperones [229, 230], target more effi-
ciently tumor areas which are poorly perfused, hypoxic or
have a low tissue pH [231]. Not only HSPs are induced with
this procedure, but also the HSF1 becomes activated, enhanc-
ing all the mechanisms to clear protein aggregates.
A more direct approach can also be assayed, i.e.  using
peptide inhibitors. For example, Nemirovsky et al. [19] used
a β-amyloid-HSP60 peptide conjugate vaccine to treat mice.
This  immunization  led  to  the  induction  of  specific  anti-
bodies that produced a significant reduction in cerebral amy-
loid accumulation. This proves that the external application
of proteins could be an alternate approach, which could be
explored properly to broaden the search for an efficient thera-
py.
The potential role of immunophilin ligands in neurode-
generative diseases needs to be investigated. It is clear that
the expression balance of the immunophilins FKBP52 and
FKBP51  plays  a  critical  role  in  the  neurodifferentiation
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[103,  232]  and  neuroregeneration  [102,  233]  process  trig-
gered  by  the  macrolide  FK506,  but  it  was  not  assayed  in
those pathologies. However, FK506 appears to target glial
cells in the brain and impairs the inflammatory reactions me-
diated by astrocytes and microglia [234], which could be of
help for the inflammatory reaction that usually accompanies
neurodegenerative diseases. However, FK506 could poten-
tially  reduce  calcineurin  activity  (which  dephosphorylates
Tau [235]) via FKBP12 inhibition and, therefore, promotes
greater Tau phosphorylation. On the other hand, it has been
shown that  FKBP51 and Tau proteins interact,  and that  in
cell culture, the overexpression of this immunophilin signifi-
cantly  increases  the  phosphorylation  of  Tau  and  total  Tau
proteins [109]. Inversely, PP5 dephosphorylates Tau and can
restore microtubule-binding function [236]. This is relevant
since both FKBP51 and PP5 are competing immunophilins
to bind GR•HSP90 complexes, and glucocorticoids increase
FKBP51 expression and are  responsible  for  major  depres-
sive disorders.
The studies published to date indicate that central and pe-
ripheral nervous systems are enriched in only five out of the
16  FKBPs  encoded  by  the  human  genome,  i.e.  FKBP12,
FKBP38, FKBP51, and FKBP52 [204], and a poorly charac-
terized FKBP of 65-kDa localized in the endoplasmic reticu-
lum that is predicted to play a role in the folding and traffick-
ing of secretory proteins [205]. Among the members of the
CyP subfamily,  the  best  studied  is  CyPA,  and  only  in  the
very recent  times,  CyP40 has been identified as  being en-
riched in the basolateral amygdala of normal mice, and it is
in reduced levels in mice showing impairments in extinction
learning capability [206]. Interestingly, these neurons show
that CyP40 colocalizes with GR, and that the extinction regu-
lating effects are inhibited by GR antagonists. This suggests
a potential role of CyP40 in post-traumatic stress disorders.
Much work needs to be done to identify unique neuro-im-
munophilins, understand their signalling pathways, the prop-
er regulatory networks, and assess their biological responses
to injury. This will greatly enhance our understanding of the
mechanisms required to promote efficient and healthy cellu-
lar neuroprotection.
Finally, new therapeutic approaches are being incipient-
ly explored. One alternative is based on the preclusion of the
abnormal  targeting  of  proteins  to  mitochondria,  i.e.,  it
favours  protection  of  normal  mitochondrial  functions  in-
creasing  neuronal  survival,  and  at  the  end,  ameliorating
symptoms of neurodegenerative disorders. In line with this
notion,  inhibitors  of  the  molecular  association  between
Hsp90/Hsp70 and the mitochondrial protein import receptor
Tom70 and TPR domain co-chaperones have been recently
designed and tested [237, 238]. One of these novel drugs is
GMP-1  (2-(methoxy-methyl)-pyrimido-[1,2-a]enzimida-
zole-4-ol,  which  was  found  to  compete  with  HSP90  for
Tom70 binding because it interacts with the TPR domains of
the translocase that participates in the recognition, unfold-
ing, and translocation of preproteins into the mitochondria,
and  shows  a  low  affinity  for  other  TPR  proteins  such  as
PP5,  FKBP51  and  Tom34.  GMP-1-treated  animals  show
lower astrogliosis and activation of microglia due to reduced
neuroinflammation [238], a phenomenon that is linked to the
reduced brain β-amyloid aggregation. Therefore, new thera-
peutic strategies based on protecting mitochondrial function
via  modulation  of  molecular  chaperone  network  are  quite
possible and open a new front to battle against neurodegener-
ative  diseases.  Today,  it  is  clear  that  the  association  of
Hsp70 and Hsp90 with co-chaperones determines the fate of
protein aggregates by clearing aberrant forms from the cell.
In such a scenario, the development of small molecule modu-
lators that can harmonize the interaction of chaperones, co-
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